Tympulse Medical
200 million adults globally have preventable disabling hearing loss, predominantly due to burst eardrums. Current solution requires surgery which takes 2-3 hours and requires general anaesthetic, harvested donor tissue and a large incision behind ear.
Tympulse Medical’s first product, TympanoColl, is a new technology for the fast and effective repair of damaged tympanic membranes. TympanoColl is an exciting combination of a new collagen based biodegradable implant with an innovative single-step delivery system to repair the ear drum via the ear canal.
The product will be supplied as a complete ENT surgical toolkit, to complete the procedure quickly, easily and safely in an outpatient setting. Reduction of surgery time to ~30 minutes (compared to three hours with current surgical procedure). Serviceable addressable market (SAM) for EU, US and Aus/ME/Asia Pacific is 480,000 cases which equates to €421m.
Promoters
- Dr John Gleeson, CEO
- Prof. Fergal O’Brien, Academic Founder
Current status
- Completed EI Commercialisation Fund
- In vivo proof of concept achieved
- Patent filed
- EI pre-seed start fund investment completed 2023
Next steps
- Seed round – €2m
- Set up small scale cGMP manufacturing site
- ISO and QMS system approval
- First-in-man [FIM] implantations